Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada
CORRECTING and REPLACING APAC Will be the Fastest Growing Market for Global Warehousing Services Market Until 2020, Reports Technavio
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.